Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia by Goette, Nora Paula et al.
Accepted Manuscript
Title: Abnormal Regulation Of Soluble And Anchored Il-6 Receptor In Mononocytes
From Patients With Essential Thrombocythemia
Authors: Nora P. Goette, Paola R. Lev, Paula G. Heller, Ana C. Glembotsky, Carlos
D. Chazarreta, Juan P. Salim, Felisa C. Molinas, Rosana F. Marta
PII: S0301-472X(10)00242-0
DOI: 10.1016/j.exphem.2010.06.007
Reference: EXPHEM 2634
To appear in: Experimental Hematology
Received Date: 13 January 2010
Revised Date: 13 June 2010
Accepted Date: 15 June 2010
Please cite this article as: Goette NP, Lev PR, Heller PG, Glembotsky AC, Chazarreta CD, Salim JP,
Molinas FC, Marta RF. Abnormal Regulation Of Soluble And Anchored Il-6 Receptor In Mononocytes
From Patients With Essential Thrombocythemia, Experimental Hematology (2010), doi: 10.1016/
j.exphem.2010.06.007
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
ABNORMAL REGULATION OF SOLUBLE AND ANCHORED IL-6 
RECEPTOR IN MONONOCYTES FROM PATIENTS WITH ESSENTIAL 
THROMBOCYTHEMIA  
Nora P. Goette, Paola R. Lev, Paula G. Heller, Ana C. Glembotsky, Carlos D. 
Chazarreta, Juan P. Salim, Felisa C. Molinas, Rosana F. Marta.  
 
Sección Hematología Investigación, UE IDIM-CONICET, Instituto Alfredo Lanari, 
Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. 
 
Corresponding author:  
Nora Paula Goette, Ph.D.  
Instituto de Investigaciones Médicas A. Lanari 
Combatientes de Malvinas 3150 
(1427) Ciudad autónoma de Buenos Aires,  Argentina 
Telephone/Fax: 54-11-45238947  
E-mail: npgoette@gmail.com 
Category:   Cytokines 
Paper word count:  4519 
Keywords: Essential thrombocythemia , monocytes, sIL-6R, IL-6R 
 
Abbreviations used in this paper:  ET, essential thrombocythemia; DS-sIL-6R, soluble 
receptor for IL-6 originated from differential splicing; PC-sIL-6R, soluble receptor for 
IL-6 originated from proteolytic cleavage; ADAM, a disintegrin and metalloproteinase 
domain;  FCS, fetal calf serum; TAPI, TNF- protease inhibitor; PBMC, peripheral 
blood mononuclear cells.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2 
ABSTRACT 
OBJECTIVE. In a previous study, we found increased plasma sIL-6R levels in patients 
with essential thrombocythemia (ET) that could promote megakaryocytopoyesis 
through IL-6 binding and further interaction with the signal transducer gp130. Here we 
have searched for the cell source of sIL-6R within mononuclear cells in these patients 
and the underlying abnormalities involved in its overproduction. 
PATIENTS AND METHODS. Thirty patients with the diagnosis of essential 
thrombocythemia were studied. sIL-6R levels were measured by ELISA technique in 
the supernatants of peripheral monocyte and lymphocyte cultures. Expression of 
membrane anchored IL-6 receptor was determined by flow cytometry.  In order to study 
the mechanism of sIL-6R production, TNF- protease inhibitor (TAPI) was added to 
specifically block IL-6R shedding. Gene expression of sIL-6R levels were evaluated by 
RT-PCR.  
RESULTS. Monocytes were the main source of sIL-6R. Besides, in ET patients, 
monocyte sIL-6R release was higher than that of controls, p = 0.0014. Lymphocytes 
enhanced monocyte sIL-6R production by cell-mediated contact in normal controls, but 
this cooperation could not be seen in patients.  Membrane expression of IL-6R was 
increased after monocyte adhesion in ET. sIL-6R synthesis was up-regulated in most 
patients while mRNA was normal.   
CONCLUSION.  Our results indicate that ET monocytes are responsible for sIL-6R 
overproduction within mononuclear cells through synthesis up-regulation.  In addition, 
the lack of cooperation of lymphocytes in monocyte sIL-6R production in ET could be 
due to a monocyte abnormality. The agonistic effect of sIL-6R on IL-6 action could 
contribute to the exacerbated megakaryocytic growth in ET. 
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INTRODUCTION 
IL-6 is a pleiotropic cytokine involved in a wide range of physiologic and pathologic 
states [1-4]. The ability of IL-6 to stimulate megakaryopoiesis has been largely 
described [5-7]. The receptor complex that mediates IL-6 intracellular signal 
transduction consists of two distinct membrane–bound glycoproteins, an 80 kDa 
specific receptor subunit (IL-6R, CD126) and a 130 kDa signal-transducing element 
(gp130, CD130). While gp130 is found in almost all cells, IL-6R expression is restricted 
to some cell types including hepatocytes and leukocyte subpopulations. In addition to 
the membrane-bound receptor, a soluble IL-6R form (sIL-6R) also possesses agonistic 
activity when bound to IL-6. The main feature of sIL-6R/IL-6 complex is its ability to 
interact with membrane-bound gp130 allowing the activation of cells that lack IL-6R in 
a process called trans-signaling [8-9].  
sIL-6R is produced by two different mechanisms. On one hand, an alternative spliced 
mRNA gives rise to a 55 kDa protein (Differential Splicing-sIL-6R, DS-sIL-6R), 
lacking the transmembrane domain. On the other hand, a soluble IL-6R form can be 
generated by proteolytic cleavage (PC-sIL-6R) of the membrane bound receptor.  The 
latter, also called shedding, has been proved to be inhibited by hydroxamic acid 
compounds [10-11]. Investigations concerning this issue showed that two members of 
the ADAM (a disintegrin and metalloproteinase domain) family of metalloproteases, 
ADAM10 and ADAM17, are involved in IL-6R shedding [12], although other proteases 
could have a minor role [13].  
Recently published studies have shown trans-signaling through the IL-6/sIL-6R 
complex as a mechanism that maintains or even causes pathological states [14]. 
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by 
increased megakaryocyte proliferation and high platelet counts [15]. Although a 
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growing amount of data is available concerning its pathological features, the molecular 
abnormalities that cause this illness are not yet fully elucidated. The presence of either 
the activating somatic mutation of the regulatory domain of the Janus Kinase 2, 
JAK2V617F, or the gain-of-function MPL mutation, MPLW515L/K, would only 
account for the phenotypic profile in about 50% of ET patients [16, 17, 18, 19]. We 
have previously reported elevated sIL-6R plasma levels in this disorder [20]. Moreover, 
raised sIL-6R concentrations in conditioned media from ET mononuclear cell culture 
were found, indicating that these cells could be one of the sources of its increased 
plasma levels. 
The aim of this study was to identify the cell type that gives rise to the increased sIL-6R 
levels among peripheral mononuclear cells in ET patients. In order to clarify the 
underlying abnormality responsible for its deregulation, we also studied the mechanism 
involved in sIL-6R production.  
 
MATERIAL AND METHODS 
Patients and controls. Thirty consecutive patients with ET were enrolled in the study. 
The diagnosis was based on clinical and laboratory features according to the 
Polycythemia Vera Study Group criteria [21]. Patients included in this study had no 
evidence of infectious or inflammatory diseases at the time of blood sample collection. 
The median age at the time of the study was 42 years old (range, 15-79), and twenty 
three were female. Only four patients were on treatment with anagrelide.  Fifteen out of 
twenty-seven patients were positive for JAK2V617F mutation, which was analyzed 
using genomic DNA from total peripheral leukocytes by means of allele-specific PCR, 
modified from that described by Jones et al [22]. DNA from three patients was not 
available. Hematological parameters from ET patients were:  leukocyte count, 8.8 10
9 
/L 
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(5.4-15.8), granulocyte count, 5.95 10
9
 /L (3.66-9.48), monocyte count, 0.41 10
9 
/L 
(0.17-0.92), lymphocyte count, 2.25 10
9 
/L (1.34-4.84), platelet count, 850 10
9
/L (230-
1365), hemoglobin levels, 13.3 g/L (10-15.8). Thirty-four healthy individuals with a 
similar age and gender were studied as controls. This investigation was approved by our 
institutional Ethics Committee (IDIM, A. Lanari) and informed consent according to the 
declaration of Helsinki was obtained from patients and healthy controls. 
 
Separation of mononuclear cells. Blood samples were drawn into sterile polypropylene 
tubes containing 342 mmol/L EDTA.  Mononuclear cells were separated by Ficoll 
Hypaque gradient (density 1.077 g/cm
3
) (SIGMA Laboratory, St. Louis, U.S.A.). Cells 
were washed once with PBS supplemented with 2 mmol/L EDTA and red blood cells 
were lysed with 0.113 mmol/L EDTA, 1 mmol/L KHCO3, 42.2 mmol/L NH4CL. 
Mononuclear cell subpopulations were statistically similar in patients and normal 
controls.  In order to minimize platelet contamination, every washing step was 
performed at 200 g and the supernatants were discarded. 
 
Purification of CD14 positive cells. Monocytes were isolated by positive selection from 
peripheral blood mononuclear cells (PBMC) using anti-CD14 antibody directly 
conjugated to magnetic beads (Miltenyi Biotec, Germany). CD14 is a molecule 
involved in LPS-mediated activation. To examine whether the positive selection or 
passage through the column promote monocyte activation, we tested two markers of 
monocyte activation, IL-1β release and IL-2Rα on the monocyte surface. We did not 
find any difference in IL-2Rα expression in purified monocytes compared to CD14-
positive cells present in PBMC from the same individual (n = 4). Besides, we evaluated 
IL-1β release from monocytes after 20-hour culture purified either by negative or by 
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positive immunomagnetic selection and found identical results in both samples. Cell 
purity was usually more than 93% pure by FACS analysis after positive selection 
(Becton-Dickinson, San José, CA, USA). CD14-negative cells were taken as purified 
lymphocytes and residual contaminating monocytes in this fraction were 0.7% (range 
0.6-3%).  
 
Cell culture. 1x10
6
 cells were incubated in 1 ml of Iscove´s Modified Dulbecco´s 
Medium (IMDM), (Gibco BRL, Gaithersburg, MD, USA) containing 10 % heat 
inactivated fetal calf serum (FCS), 15 g/ml penicillin and 15 g/ml streptomycin 
(Gibco BRL) on polystyrene plaques (TPP, Trasadingen, Switzerland) at 37ºC in 5% 
CO2 atmosphere. Viability of cultured cells was over 92%. After 18 hours, the 
supernatants were collected, centrifuged and stored at –70ºC. Assays were performed in 
triplicate. For metalloprotease inhibition studies, TNF- protease inhibitor (TAPI, 
Peptides International, USA), was added to culture media at a final concentration of 200 
mol/L, and samples were processed as previously described.   
For studies of cell cooperation, purified fractions were incubated with 1% 
paraformaldehyde for 5 minutes at 4ºC. Albumin 1.5% was added to inactivate 
paraformaldehyde and after a washing step, cells were seeded as detailed in Table 1, and 
cultured as described above.  
 
sIL-6R measurement in cell culture supernatants. sIL-6R levels in supernatants from 
PBMC and purified cells culture were assayed by ELISA technique (R&D Systems, 
Minneapolis, USA). The lower detection limit according to the manufacturers was 6.5 
pg/ml.  Intra-assay and inter-assay variations were lower than 5.2% and 9.2%, 
respectively. 
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Evaluation of IL-6R on cell membrane by flow cytometry. Monocytes and T-
lymphocytes were individualized by the addition of specific monoclonal antibodies 
(mAbs) directed against CD45 labeled with PerCP and anti CD14 and CD3 labeled with 
FITC (Becton-Dickinson) respectively. IL-6R was identified by incubation with anti 
CD126-PE antibody (Immunotech, Coulter Co). Irrelevant mAbs of the same Ig 
subclass were used as negative controls. Samples were analyzed by a FACScan flow 
cytometer (Becton-Dickinson) and results we expressed as percentage of CD126-
positive population in T-lymphocytes and monocytes compared to the corresponding 
isotype control.  
  
Real Time RT-PCR for sIL-6R and IL-6R expression. mRNAs for DS-sIL-6R  and IL-6R 
isoforms (IL-6R+sIL-6R) and for DS-sIL-6R alone were detected by real-time RT-PCR. 
Total monocyte RNA was isolated after culture using Trizol reagent (Gibco-BRL) from 
1.2 x 10
6
 cells according to Chomcynski and Sacchi [23]. cDNA was synthesized from 
1g RNA using the Super ScriptTM preamplification system (Gibco-BRL) according to 
the manufacturer’s instructions. Real-time PCR was performed using IQTM SYBR 
Green Supermix (Bio-Rad, Life Science, Ca) in an iCycler iQ Real-Time PCR System 
(Bio-Rad). Quantification was carried out using GAPDH expression as an internal 
normalization control in both PCR studies. Annealing temperature was set at 64°C in all 
cases. Primer sequences for sIL-6R were: forward 5´-GCGACAAGCCTCCCAGGTTC-
3´ (directed to the specific sequence generated by alternative splicing, spanning bases 
1488 to 1503 followed by bases 1598 to 1601 in the membrane IL-6R, which 
corresponds to bases 1488 to 1506 in the sIL-6R) and reverse 5´-
GTGCCACCCAGCCAGCTATC-3´ (bases 1746 to 1765), as previously described 
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[24]. To quantify IL-6R+sIL-6R mRNA, a fragment common to both, the anchored and 
soluble isoforms, was amplified using the following forward 5’-
CCAGCATCACTGTGTCATCC-3’ and reverse 5’-TCCTGGATTCTGTCCAAGGC-3 
primers (bases 1256 to 1395). Primer sequences for GAPDH were: forward 5´-
CGACCACTTTGTCAAGCTCA-3´ and reverse 5´-CCCTGTTGCTGTAGCCAAAT-
3´. Quantitative normalization of cDNA in each sample was obtained by the  cycle 
threshold (Ct) method (sIL-6R Ct – GAPDH Ct) or [(IL-6R+sIL-6R) Ct – GAPDH Ct]. 
Melting curve analysis and electrophoresis in 2% agarose gel followed by ethidium 
bromide staining were performed to confirm the identity of PCR products. Each sample 
was assayed in triplicate, and a negative control was included in each assay.   
 
Statistical analysis. All values were expressed as median and range. Correlations 
between two variables were analyzed using Spearman’s rank correlation coefficient. 
Mann–Whitney U-test was used to compare variables between two groups (patients and 
normal controls). Wilcoxon matched-pairs signed-ranks test was performed to compare 
monocyte IL-6sR production from different samples of the same individual.  p < 0.05 
was considered statistically significant; all p values presented are two-sided.  
 
RESULTS 
ET monocytes are responsible for sIL-6R increase in mononuclear cell cultures 
sIL-6R in the supernatant of mononuclear cell cultures 
 In accordance to our previous results [20], samples from ET patients (n = 20) displayed 
higher sIL-6R than those from normal controls (n = 18), 124.5 (74.0-357.1) pg/10
6
 cells 
and 85.4 (35.7-161.0) pg/10
6
 cells, respectively, p = 0.0024. Wells seeded with platelets 
in a concentration similar to that found contaminating mononuclear cells (1x10
3
 to 
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1x10
5
 platelets per well) yielded undetectable sIL-6R levels. There was no correlation 
between sIL-6R levels in conditioned media and monocyte (r = 0.24, p = 0.26) or 
lymphocyte (r = -0.16, p = 0.44) percentage in the culture fraction.  
 
sIL-6R release by purified cells 
With the aim of identifying the cellular source of sIL-6R among mononuclear cells in 
ET patients, we performed cell culture from purified monocytes and lymphocytes 
separately. sIL-6R released from monocytes was higher than that released from 
lymphocytes in both, patients (p = 0.0001) and controls (p = 0.0002), (Figure 1). 
Furthermore, sIL-6R production from purified monocytes was higher in all ET patients 
(n = 18) than controls (n = 13), 511.9 pg/ml (243.5-815.7) vs 212.7 pg/ml (130.0-
499.7), p = 0.0014. Monocytes from patients under anagrelide treatment produced 465.5 
pg/ml (296.0- 653.9), n = 4. Notably, the amount of sIL-6R released by purified 
lymphocytes was very low, in some cases below  the  detection limit of the ELISA, in 
patients 23.8 pg/ml, (6-56.6) as well as in controls, 22.2 pg/ml, (0-44.3),  p = NS. This 
production could be attributed to residual monocyte contamination in purified 
lymphocytes. Taken together, these results indicate that monocytes are the main source 
of sIL-6R within mononuclear cells. 
In order to compare sIL-6R production rate in monocytes from mononuclear cell culture 
and the purified fraction, the amount of sIL-6R produced by 10
4 
monocytes was 
calculated in both samples (mononuclear cells and purified monocytes) taking into 
account the percentage of CD14+ cells and the total number of seeded cells. 
Considering that CD14 negative cell culture produced less than 10% of that of 
monocytes, sIL-6R levels in wells with mononuclear cells was exclusively attributed to 
monocytes. sIL-6R production rate from purified monocytes was lower than that 
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obtained from monocytes cultured with autologous lymphocytes 4.30 (2.0-9.1) pg/10
4
 
cells vs 9.8 (6.2-76.1) pg/10
4 
cells,  p = 0.0004, (eight patients and six normal controls 
were analysed) suggesting that interaction between both cell types promotes sIL-6R 
release.  
Cooperation between monocytes and lymphocytes in sIL-6R production 
To further investigate if interaction between monocytes and lymphocytes could promote 
sIL-6R release we designed a cell culture protocol where monocytes were co-cultured in 
the presence of lymphocytes,  either viable or formolized. Wells with living or 
formolized lymphocytes were also seeded. Four normal controls and five patients were 
studied (Table 1). These results clearly confirm that monocytes are the main cell source 
of sIL-6R. In normal samples, the sum of sIL-6R produced by isolated monocytes and 
isolated lymphocytes cultured separately (wells 1+4, Table 1) was lower than that 
obtained when both cell types were co-cultured (well 2), p = 0.005, demonstrating a 
cooperation between monocytes and lymphocytes in sIL-6R production. Moreover, the 
presence of either living or formolized lymphocytes in monocyte culture induced an 
increase in sIL-6R to a similar extent, suggesting that direct cell contact instead of 
soluble mediators release, is the mechanism involved in monocyte-lymphocyte 
interaction. Surprisingly, cooperation between monocytes and lymphocytes was not 
evident in patients’ samples revealing an abnormal sIL-6R regulation in ET. In order to 
find out whether this abnormality was due to a low lymphocyte stimulation or a 
decrease of monocyte response to lymphocyte stimulation, ET monocytes were co-
cultured in the presence of  formolized autologous lymphocytes or formalized 
heterologous normal lymphocytes and vice versa. Samples from 3 patients and 3 normal 
controls were tested. As shown in Table 2, sIL-6R levels produced by ET monocytes in 
the presence of both, autologous or normal lymphocytes were similar. The same results 
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were found when normal monocytes were evaluated. These data strongly suggest that 
the lack of cooperation between monocytes and lymphocytes in ET is due to a 
monocyte abnormality. With the aim of testing whether soluble mediators produced by 
monocytes could induce lymphocyte sIL-6R production, viable lymphocytes were 
cultured in the presence of monocytes’ conditioned media. sIL-6R levels measured in 
the supernatant of cultured lymphocytes in these conditions were similar to those found 
in monocytes’ conditioned media (two samples were tested, one from a normal control 
and one from a patient) indicating that lymphocytes are not stimulated by monocytes’ 
soluble mediators  in our culture conditions. Finally, we analyzed whether monocytes 
could induce lymphocyte sIL-6R production through direct cell contact. For this 
purpose we cultured living lymphocytes with autologous formolized monocytes from 
three normal individuals. sIL-6R levels in these wells, 33 pg/ml, 20-45,  were similar to 
those found in wells containing isolated lymphocytes (Table 1, well 4),  disregarding 
this possibility.  
 
Evaluation of the mechanism of sIL-6R production 
 IL-6R on the monocyte membrane 
 IL-6R expression on cell surface reflects the balance between synthesis and proteolytic 
cleavage. When monocytes are stimulated by shedding inducers, membrane expression 
of IL-6R decreases [25]. In an attempt to evaluate whether IL-6R cleavage was 
increased in ET patients, we studied its expression on monocyte surface by flow 
cytometry using anti-CD126-PE. In basal conditions, IL-6R, expressed as percentage of 
CD126-positive monocytes in ET patients, was similar to that found in normal 
counterparts, 4.7 % (1.8-32.5) (n = 11) and 6.4% (0.9-33.2) (n = 12), respectively, p = 
0.22. When evaluated after mononuclear cell culture, ET monocytes had higher IL-6R 
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membrane expression than normal controls, 9.5% (1.5-27.0%) and 4.1 % (0.10-16.0) 
respectively, p = 0.03. We then calculated the difference between IL-6R membrane 
expression after culture (T2) and in basal conditions (T1):  CD126 (T2 – T1) in both, 
patients and normal controls. ET patients showed a positive  CD126, 6.5% [(-9.6)-
(13.5)], compared to a negative  CD126 in normal controls, -4.5 [(-17.3)-(10.7)], p = 
0.0364 (Figure 2). These results demonstrate IL-6R up-regulation in ET monocytes and 
IL-6R down-regulation on normal monocytes during culture, disregarding shedding as a 
mechanism underlying the increase in sIL-6R in ET. On the contrary, T-lymphocytes 
from both ET patients (n = 8) and normal controls (n = 7) displayed similar IL-6R 
membrane levels in basal conditions, 30.1 (12.5-47.5) % vs 29.5 (4.9-68.1) % 
respectively, p=NS, as well as after PBMC culture, 13.4 (2.1-41.7) % and 19.2 (10.3-
35.9) %, respectively, p = NS. These results suggest that the IL-6R abnormalities are 
restricted to the monocyte lineage and that other immune cells are unaffected.   
 
sIL-6R production after inhibition of shedding by TAPI 
To confirm that shedding is not responsible for the higher production of sIL-6R found 
in ET, we tested the effect of direct inhibition of metalloproteases involved in IL-6R 
cleavage on monocyte sIL-6R release. For that purpose, we performed monocyte 
cultures with the addition of the metalloprotease inhibitor TAPI [11]. In these 
conditions, sIL-6R production would be mainly due to de novo synthesis although 
minor contribution of other proteases not inhibited by TAPI cannot be excluded [13]. 
When TAPI was added, conditioned media from ET monocytes (n = 11) had higher sIL-
6R concentrations than those obtained from normal monocytes (n = 10), 340.7 (121.0-
731.5) pg/ml vs 193.9 (82.5-335.0) pg/ml, respectively, p = 0.011 (figure 3), indicating 
that de novo synthesis of sIL-6R is increased. We then calculated the difference between 
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sIL-6R produced when monocytes were cultured alone (total sIL-6R) and with the 
addition of the metalloprotease inhibitor (TAPI-inhibited sIL-6R production), which 
mainly represents sIL-6R produced by shedding due to ADAM 10 and ADAM17 
activity [12]. Results obtained from ET patients were similar to those of normal 
controls, 134 pg/ml (35.5-494.0) and 92.5 pg/ml (21.0-215.0) respectively, p=0.35, 
supporting the fact that IL-6R shedding is not increased in ET monocytes.  Figure 4 
illustrates the contribution of each mechanism to sIL-6R production in every sample 
(patients, left; controls, right). As shown, nine out of eleven patients had higher sIL-6R 
levels in the presence of TAPI than the normal median value. However, contribution of 
both mechanisms to sIL-6R increase was observed in patient 5. 
 
Quantification of mRNA isoforms generated from the IL-6R gene 
In order to evaluate monocyte sIL-6R production by differential splicing, sIL-6R RNA 
levels were measured in purified monocytes from 7 ET patients and 7 normal controls 
by real time RT-PCR. The median Ct value for ET monocytes was similar to that of 
controls, 7.54 (5.24-9.86) and 6.75 (5.97-8.98), respectively, p = 0.8 (Figure 4). We also 
investigated the expression of the total mRNA isoforms arising from IL-6R gene, 
corresponding to the soluble and anchored isoforms, by using primers that amplify a 
sequence common to both. The median Ct were 3.82 (-1.85-5.70) and 4.82 (1.5-6.3) 
for patients (n = 8) and normal controls (n = 8) respectively, p = 0.28. These results 
demonstrate that sIL-6R and IL-6R mRNA levels were not affected in ET patients, thus 
raising the possibility of a post-transcriptional abnormality.  
 
Correlation between clinical and experimental parameters 
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No correlation was found between either haemoglobin levels, platelet, leukocyte, 
granulocyte, monocyte and lymphocyte counts and any of the experimental parameters 
measured in this cohort, including sIL-6R levels in mononuclear and monocyte culture 
supernatants, IL-6R in monocyte membrane or IL-6sR production in the presence of 
TAPI. sIL-6R levels in mononuclear cell culture in JAK2V617F-positive and 
JAK2V617F–negative patients were 139.5 pg/ml (88.0-357.1) and 123.0 pg/ml (74.7-
197.3), respectively, while sIL-6R levels in monocyte conditioned media were 641.9 
pg/ml (296.0-815.7) and 417.9 pg/ml (243.5-772.0),  respectively. Individual sIL-6R 
levels and clinical data are listed in Table 3 as Supplemental Material.  Monocyte sIL-
6R production in the presence of TAPI was 346.7 pg/ml (212.5-731.5) and 307.7 pg/ml 
(121.0-524.0) in patients with or without the mutation, respectively, while IL-6R on the 
monocyte surface was 12.2 % (5.7-27.0) and 8.1% (1.5-22.9), respectively. Although 
none of these experimental parameters were significantly different in both groups of 
patients, it is remarkable that minimum, maximum and median values were always 
higher in the group of patients with the mutation (Figure 5). 
 
 
DISCUSSION 
Trans-signaling through sIL-6R is a key contributing pathologic mechanism in immune 
disorders, such as rheumatoid arthritis and inflammatory bowel disease, [1, 2, 3) as well 
as in non-immune entities like cancer or hypertension [26, 27]. In the present study, we 
have shown that monocytes from patients with ET are at least one of the sources of the 
raised plasma sIL-6R we have previously described in this myeloproliferative neoplasm. 
The elevated sIL-6R levels could contribute to the high platelet production by 
increasing megakaryocyte response to IL-6 [28, 29]. It is interesting to note that 
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thrombocytosis, the hallmark of ET, is a common feature in inflammatory and 
neoplastic entities, and high sIL-6R levels are also present in some of these disorders 
[30].  
A number of reports have described sIL-6R production from normal monocytes or 
monocytic cell lines [12, 31]. Indeed, in normal controls, monocytes are the main source 
of sIL-6R in mononuclear cell culture, in the absence of stimulus other than FCS. 
However, lymphocytes are able to release sIL-6R under specific conditions such as 
TCR activation [32] and HTLV-transformation [33]. Therefore, the possible 
contribution of ET lymphocytes to sIL-6R increase was also considered. According to 
our results, sIL-6R production by non-stimulated lymphocytes was low, and contact 
with monocyte soluble or membrane factors was not efficient to trigger sIL-6R release 
by these cells. On the contrary, monocytes accounted for the sIL-6R release and 
reproduced the abnormal behavior seen in ET mononuclear cells in culture.  
 Noteworthy, sIL-6R released by normal isolated monocytes was lower than that found 
when monocytes were co-cultured with autologous lymphocytes, suggesting that these 
cells could potentiate sIL-6R release. Therefore, cooperation between both cell types 
was considered. We clearly demonstrate here for the first time that contact-mediated 
monocyte stimulation by lymphocytes increases monocyte sIL-6R release. Our results 
are in agreement with previously published data indicating that, contact-mediated 
signaling of monocytes by stimulated T cells is a potent mechanism that induces up-
regulation of pro-inflammatory cytokines. However, it is important to remark that, in 
our study, lymphocytes were not treated with any activating agent. Interestingly, 
cooperation of lymphocytes in monocyte sIL-6R release was more evident in normal 
controls than in ET patients. When normal or ET fixed lymphocytes were tested to show 
their capacity to induce monocyte stimulation, we found the same response to both 
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stimuli, either in ET or normal monocytes, indicating a normal behavior of ET 
lymphocytes, and pointing to monocytes as responsible for the abnormal interaction.  
In order to clarify the mechanism responsible for sIL-6R production, and taking into 
account that the anchored receptor could be the source of its soluble form by proteolytic 
cleavage, we also assessed IL-6R membrane expression in basal conditions and after 
cell culture. We found abnormal changes on monocyte IL-6R expression in ET patients; 
while the anchored receptor tended to decrease during culture in normal monocytes, as 
already described [34], IL-6R expression increased after 18 hours of cell culture in 
samples from ET patients, suggesting synthesis up-regulation. In addition, we 
performed monocyte culture in the presence of TAPI, a well-known inhibitor of 
ADAM10 and ADAM17. These metalloproteases are the main enzymes involved in IL-
6R shedding. In ET patients, sIL-6R released by ADAM activity was found normal. 
However, a minor contribution to sIL-6R production by proteolytic cleavage due to 
proteases that are not inhibited by TAPI must also be considered [13]. This possibility 
seems unlikely as, if the latter mechanism took place in ET monocytes, a decrease in IL-
6R should be noted on the cell membrane, in contrast to our findings. Overall, the 
absence of surface IL-6R down-regulation in ET monocytes during adhesion, together 
with the persistence of high sIL-6R in the culture supernatant after metalloprotease 
inhibition by TAPI, suggest that proteolytic cleavage is not responsible for the raised 
sIL-6R levels in conditioned medium, and point to synthesis up-regulation as the 
possible mechanism involved in the increased sIL-6R production. Considering that the 
elevated sIL-6R protein could be the consequence of an enhanced transcription rate, we 
also assessed the expression of DS-sIL-6R at the RNA level. Surprisingly, real time 
PCR analysis indicated that monocyte sIL-6R RNA was not increased, ruling out this 
hypothesis. Similarly, anchored IL-6R expression was also normal in cDNA from 
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adherent ET monocytes when semi-quantitative PCR analysis was carried out (data not 
shown) and mRNA corresponding to both IL-6R isoforms (IL-6R+sIL-6R) was not 
increased by Real Time RT-PCR.  Of note, both proteins, sIL-6R and IL-6R, arising 
from the IL-6R gene, were found up-regulated during culture in monocytes from ET 
patients, while increased transcription rates were disregarded. It could be hypothesized 
then that IL-6R and sIL-6R protein levels are enhanced due to post-transcriptional 
regulation. Concerning this issue, IL-6R and/or sIL-6R protein modulation at this level 
has, to our knowledge, not been reported. However, post transcriptional regulation was 
described for other receptors, such as CXCR-4 [35]. Another possibility is that post-
translational changes in both proteins lead to decreased turnover. Four N-glycosylation 
sites have been described for membrane IL-6R [36] but their role in protein stability has 
not been studied yet. Interestingly, N-linked glycosylation has been proved to be 
essential for the stability in gp130 [37]. Studies on IL-6R and sIL-6R stability might 
shed light in this matter.  
During their life-time, circulating monocytes are recruited to tissues, where they adhere 
to matrix proteins triggering their transformation into macrophages. Cellular adhesion in 
culture mimics these events and macrophages can be obtained after 10 days of culture. 
Our in vitro observations of overexpression of the membrane-bound IL-6 receptor and 
up-regulated soluble form release could take place in vivo in tissue macrophages, 
enhancing their response to IL-6 and increasing the sensitivity of surrounding cells to 
this cytokine by the trans-signaling mechanism.  
Monocytes have been shown to play a role in thrombosis in ET [38] as well as in other 
myeloproliferative neoplasms, such as primary myelofibrosis [39]. Indeed, evidence of 
monocyte activation, such as increased levels of membrane tissue factor [38] and 
elevated levels of IL-2R on the cell surface [40] were found in these entities. This 
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activated status could be the consequence of the clonal origin of ET monocytes or be 
triggered by monocyte interaction with activated platelets. The increased monocyte sIL-
6R production we describe here is another evidence of the abnormal behavior of these 
cells in this disease.  
In summary, the present study unveils monocytes as one of the sources of sIL-6R 
increase in ET patients. Abnormal regulation of the IL-6 receptor is demonstrated by 
up-regulation of anchored IL-6R on cultured monocytes, increased sIL-6R synthesis and 
abnormal monocyte response to cooperation with lymphocytes on sIL-6R production. 
These findings highlight the pathogenic role of monocytes in myeloproliferative 
neoplasms. The agonistic nature of sIL-6R on IL-6, a well-known megakaryopoietic 
inducer, could contribute to the exacerbated megakaryocytic growth in essential 
thrombocythemia.   
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FIGURE LEGENDS  
 
Figure 1. sIL-6R levels in the supernatant of 18-hr cell cultures.  sIL-6R released 
from purified monocytes and lymphocytes.  CD14 positive cells from 18 ET patients 
and 13 normal controls (C) were obtained by immunomagnetic selection and cultured 
for 18 hs.  Negative fractions containing total lymphocytes were cultured separately in 
the same conditions.  M and L indicates sIL-6R levels in conditioned media from 
monocytes and lymphocytes respectively. The median values are shown as horizontal 
lines in the box. sIL-6R production from ET monocytes was significantly higher than 
that of their normal counterparts,  p = 0.0014.  
 
Figure 2. Variations in IL-6R monocyte expression before and after culture. IL-6R 
on monocyte membrane was evaluated by flow cytometry using a specific antibody 
(CD126-PE). The difference between IL-6R membrane expression after culture (T2) 
and in basal conditions (T1), CD126 (T2-T1), in ET patients (n=11) and controls 
(n=12) are shown, p = 0.0364. 
 
Figure 3. Monocyte sIL-6R production in the presence of TAPI. a) Monocytes from 
11 ET patients (ET) and 10 normal controls (C) were cultured in the presence of TAPI. 
sIL-6R was measured by ELISA. Y axis indicates sIL-6R levels during metalloprotease 
inhibition. Mann–Whitney U-test show a significant difference between groups (p = 
0.011). b) Contributing mechanisms to sIL-6R production in each patient or c) normal 
control. Dark bars refer to sIL-6R released during metalloprotease inhibition, mainly 
produced by de novo synthesis. Light bars show sIL-6R produced by shedding, 
calculated as the difference between total and TAPI-inhibited sIL-6R release. In the 
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presence of TAPI, median values of released sIL-6R were 340.7 pg/ml and 193.9 pg/ml, 
for patients and controls, respectively. 
 
Figure 4. Expression levels of sIL-6R and IL-6R mRNA in monocytes. Purified 
monocyte samples were tested for sIL-6R mRNA and for both isoforms (IL-6R+sIL-6R) 
by real time RT-PCR using GAPDH as an internal control. Results are expressed as 
Ct. a) sIL-6R mRNA levels in 7 ET patients and 7 normal controls, p=0.8. b) IL-
6R+sIL-6R mRNA levels in 8 ET patients and 8 normal controls, p = 0.2. 
 
Figure 5. Experimental data according to JAKV617F status.  sIL-6R production by a) 
mononuclear cells, b) purified monocytes and c) purified monocytes in the presence of 
TAPI from  patients with wild type JAK2 (WTJAK2) and from patients with the 
JAK2V617F mutation. d) CD126 expression on monocyte membrane after culture in 
patients with JAK2 mutation and patients without the mutation. The number of patients 
included in each group is shown above the box.  
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Table 1: Study of cellular interaction in sIL-6R production 
 
 
 
Well Cell type seeded Patients 
sIL-6R (pg/ml) 
Controls 
sIL-6R (pg/ml) 
1 Monocytes 389 (296-654) 163 (108-306) 
2 Monocytes + lymphocytes 414 (366-673) 276 (185-370) 
3 Monocytes + formolized lymphocytes 430 (343-665) 273 (181-360) 
4 Lymphocytes 42 (26-44) 10 (2-27) 
5 Formolized lymphocytes 11 (2-22) 3 (0-10) 
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Table 2: Monocyte stimulation by autologous and heterologous lymphocytes 
 
 
Patient  
 
ET Mo+fixed autologous Lym 
(sIL-6R pg/ml) 
 
 
ET Mo+fixed normal Lym 
(sIL-6R pg/ml) 
P1 
 
466.7 480.2 
P2 
 
656.8 686.3 
P3 
 
854.0 811.0 
 
Normal control 
 
Normal Mo+fixed autologous Lym 
(sIL-6R pg/ml) 
 
 
Normal Mo+ET Lym 
(sIL-6R pg/ml) 
N1 
 
272.2 328.0 
N2 
 
441.4 431.9 
N3 
 
541.0 529.1 
 
Abreviations: Mo, monocytes; Lym, lymphocytes; P,  patient; N,  normal control. 
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